Top

Published in:

01-07-2015 | Erratum

Erratum to: Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study

Authors: Nuriye Ozdemir, Huseyin Abali, Murat Vural, Suayib Yalcin, Berna Oksuzoglu, Burak Civelek, Dilek Oguz, Birol Bostanci, Bulent Yalcin, Nurullah Zengin

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2015

Excerpt

Unfortunately, the part of acknowledgement detail was omitted in the published article and the below line must be considered as the last sentence. …

Title: Erratum to: Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study
Authors: Nuriye Ozdemir
Huseyin Abali
Murat Vural
Suayib Yalcin
Berna Oksuzoglu
Burak Civelek
Dilek Oguz
Birol Bostanci
Bulent Yalcin
Nurullah Zengin
Publication date: 01-07-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-015-2797-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2015

Development of a new equation to estimate creatinine clearance in cancer patients

Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations

Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer

A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer

Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma

Direct and indirect targeting of MYC to treat acute myeloid leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer